:

Babak Arjmand1, Somayeh Jahani Sherafat2, Mostafa Rezaei Tavirani3

  • 1Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

概括

这项研究确定了AKT1和HRAS是肝癌中关键的失调蛋白,为改善诊断和向治疗提供了潜在的生物标志物. 这些发现突出了未来肝癌治疗策略的关键途径.